Product Description
Nippon Kayaku was developing nk-012, an intravenous TOP Inhibitor,DNA Synthesis Inhibitor for advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01238952)
Mechanisms of Action: TOP Inhibitor,DNA Synthesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nippon Kayaku
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Myeloma|Small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Cancer
Phase 1: Colorectal Cancer|Triple Negative Breast Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A6012211US | P2 |
Completed |
Triple Negative Breast Cancer |
2014-12-01 |
|
| JapicCTI-111652 | P2 |
Completed |
Multiple Myeloma |
2014-09-01 |
|
| A6012113US | P1 |
Completed |
Colorectal Cancer |
2013-12-01 |
|
| A6012212US | P2 |
Completed |
Small Cell Lung Cancer |
2012-01-01 |